STOCK TITAN

Journey Medical Corporation (DERM) Stock News, Nov 8-16, 2021

DERM NASDAQ

Journey Medical Corporation develops, sells and markets FDA-approved prescription pharmaceutical products for dermatological conditions. The company is a commercial-stage dermatology pharmaceutical issuer with a portfolio of branded prescription drugs marketed in the United States.

Recurring news for DERM centers on quarterly and annual financial results, corporate updates, and commercialization progress across its dermatology portfolio. Company updates frequently discuss Emrosi™, a modified-release minocycline product approved for inflammatory lesions of rosacea in adults, including payer access, group purchasing organization contracts, prescription demand, product revenue, and clinical data presentations or publications for Emrosi/DFD-29.

Rhea-AI Summary

Journey Medical Corporation (NASDAQ: DERM) has closed its initial public offering, successfully selling 3,520,000 shares at $10.00 each, raising gross proceeds of $35.2 million. The proceeds will be allocated towards general corporate purposes, including research and development, marketing, and potential acquisitions. The offering was managed by B. Riley Securities, with Roth Capital Partners as a co-manager. Journey Medical specializes in dermatological products and aims to leverage its capital for growth in the competitive pharmaceutical market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.83%
Tags
-
Rhea-AI Summary

Journey Medical Corporation (NASDAQ: DERM) has priced its initial public offering (IPO) at $10 per share, raising gross proceeds of $35.2 million. The company, a subsidiary of Fortress Biotech (NASDAQ: FBIO), will receive approximately $31.4 million in net proceeds after expenses. The IPO is set to close on November 16, 2021, with common stock starting to trade on November 12, 2021. Proceeds will support working capital, R&D, marketing, and potential acquisitions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Journey Medical Corporation has launched an initial public offering (IPO) of 3,200,000 shares of common stock, expected to price between $10 and $12 per share. The company, a subsidiary of Fortress Biotech (FBIO), may also allow underwriters to purchase an additional 480,000 shares. Journey Medical aims to list its shares on The Nasdaq Capital Market under the symbol ‘DERM.’ B. Riley Securities is the sole book-running manager, with Roth Capital Partners as a co-manager. The offering is subject to market conditions and regulatory approval.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags

FAQ

What is the current stock price of Journey Medical (DERM)?

Journey Medical (DERM) last closed at $3.90.

What is the market cap of Journey Medical (DERM)?

The market cap of Journey Medical (DERM) is approximately $110.1M.